Trial Profile
Phase 1 Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) With Expansion in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs MVT 5873 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Colon cancer; Lung cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors BioNTech; MabVax Therapeutics
- 22 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Oct 2026.
- 22 Feb 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Aug 2024.
- 20 Jan 2024 Results (n=97) assessing safety and efficacy of BNT321 as monotherapy and in combination with mFOLFIRINOX in patients (pts) with advanced CA19-9 expressing cancers presented at the 2024 Gastrointestinal Cancers Symposium